Where does Assembly Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Assembly Biosciences, Inc. ranks #19,468 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Assembly Biosciences, Inc. hold?

Assembly Biosciences, Inc. holds 14 US utility patents granted between 2019 and 2024, spanning 4 technology areas.

What is Assembly Biosciences, Inc.'s Innovation Score?

Assembly Biosciences, Inc. has an Innovation Score of 27.5 out of 100 (24th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Assembly Biosciences, Inc. focus on?

Assembly Biosciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 13 patents, ranking #1,479 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Assembly Biosciences, Inc.'s patent grant rate increasing or decreasing?

Assembly Biosciences, Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Assembly Biosciences, Inc.'s patents?

Assembly Biosciences, Inc.'s patents average 15.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Assembly Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Assembly Biosciences, Inc.

USPTO PatentsView assignee record - 14 granted patents across 4 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Assembly ranks #19,468 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 4 technology areas.

#19,468
of 49,997 US assignees by volume: 24th percentile
by Innovation Score (27.5/100): 15.4
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19468 · US Corporation #19,468 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,468/49,997
PHOTO-FINISH Arcachon Holdings
CPC-NARROW A61P · 4 areas
INNOV-THIN 27.5/100
CLAIMS-RICH 15.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arcachon Holdings LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Assembly’s 27.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (34%) Velocity 1.8 pts (7%) Breadth 7.1 pts (26%) Claim depth 9.3 pts (34%)

Qualcomm Incorporated · highest

85
Assembly Biosciences · this assignee

28
3D Lighting… · lowest

7

What this shows Assembly's Innovation Score is 27.5/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Assembly?

Each dot is one of Assembly’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Assembly’s own 15.4 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Assembly vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Assembly's grants concentrate

Assembly Biosciences, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 92.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (6 grants) versus a trough of 1 in 2020. By volume, Assembly sits between Arcachon Holdings LLC and Audio Analytic Ltd.

Assembly's three-year grant acceleration

Assembly Biosciences, Inc. shows 3 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Arcachon Holdings

14
Archangel Device

14
Arkimos

14
Arysta Lifescience

14
Assure Tech (Hang…

14
Aswan Internation…

14
Athena Automation

14
Audio Analytic

14
Assembly Bioscien… ◀

14

What this shows Assembly holds 14 patents at rank #19,430, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Assembly

By rank, the assignees closest to #19,430 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Assembly's primary technology class.

Assembly's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 24th percentile higher than 24% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Assembly Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	4	28.6%
2020	1	7.1%
2021	6	42.9%
2023	2	14.3%
2024	1	7.1%

Which technologies does Assembly Biosciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

C07D - Heterocyclic Compounds 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07C - Acyclic OR Carbocyclic Compounds 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Assembly Biosciences, Inc.'s patent record in context - here's where to go next.

Assembly Biosciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #19,468 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Assembly Biosciences, Inc. against Arcachon Holdings LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.